JUPITER, Fla., April 06, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (OTCQX:DYAI) (“Dyadic”), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that Stephen Warner has resigned from the Board of Directors of Dyadic (the 'Board'), effective June 1, 2017. His service on the audit, compensation, and nominating committees will also end at that time.
Mr. Warner has served on Dyadic’s board of directors since October 2004. "We appreciate Mr. Warner’s valuable contributions over the past twelve years, including his support during our litigation against our former professional service providers, his guidance in the Company’s turnaround and sale of Dyadic’s Industrial Biotechnology business to DuPont’s Industrial Biosciences," said Michael Tarnok, Dyadic’s Chairman. Mr. Tarnok further commented that, "The Board and management of Dyadic would like to thank Steve for his service to Dyadic and we wish him well in his other current and future endeavors."
"I truly enjoyed my twelve years of service on Dyadic’s board and I am very proud of what we have been able to accomplish with our limited resources. Dyadic is now well capitalized and is positioned to expand its presence in the biopharmaceutical industry. l believe in Dyadic’s future and look forward to the realization of the full potential of our C1 technology and our biopharmaceutical business. I plan on remaining a shareholder, and wish all the best to the company and its very capable management,” said Mr. Warner.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical protein production system based on the fungus Myceliopthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, production and performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research & development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in developing and manufacturing biopharmaceuticals which these technologies help produce. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly saving lives.
Please visit Dyadic’s website at www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) Dyadic’s ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; (8) the receipt of the settlement payment by Dyadic from Greenberg Traurig, LLP and Greenberg Traurig, P.A. and; (9) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our December 31, 2016 Annual Report (with Amended Audit Report) filed with the OTC Markets on March 24, 2017. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.